Numerous studies using models of cerebral ischemia in rodents indicate that Liraglutide reduces the volume of the infarct zone, has a neuroprotective and antioxidant effect, promotes angiogenesis and increases the expression of VEGF in the area of cerebral ischemia [76,77,78], improves metabolic and functional recovery after stroke [79], and reduces neurological deficits [80,81,82]. This evidence concerns the gene VEGFA and Stroke.